Hunan Warrant Pharmaceutical (688799.SH): Approval Notice for Listing Application of Chemical Raw Material Bismuth Potassium Citrate

Hunan Warrant Pharmaceutical (688799.SH) announced that it recently received a Approval Notice for the Bi-Potassium Citrate Bismuth Chemical API (Notification No: 2025YS00164) issued by the National Medical Products Administration. The approval was also published on the Chemical Drug Evaluation Center (CDE) platform for the registration information of chemical APIs, excipients, and pharmaceutical packaging materials. The company's chemical API Bi-Potassium Citrate Bismuth has obtained the Approval Notice for Market Application, indicating that the raw material has met the relevant technical standards for drug evaluation in the country and has been approved for use in domestic formulations. This will further enrich the company's product line and enhance its core competitiveness. Currently, the Bi-Potassium Citrate Bismuth chemical API is not yet available for sale, due to uncertainties related to GMP compliance inspections and changes in the market environment.